SI3043785T1 - Uporaba R-ketamina in njegove soli kot farmacevtska sredstva - Google Patents
Uporaba R-ketamina in njegove soli kot farmacevtska sredstvaInfo
- Publication number
- SI3043785T1 SI3043785T1 SI201431903T SI201431903T SI3043785T1 SI 3043785 T1 SI3043785 T1 SI 3043785T1 SI 201431903 T SI201431903 T SI 201431903T SI 201431903 T SI201431903 T SI 201431903T SI 3043785 T1 SI3043785 T1 SI 3043785T1
- Authority
- SI
- Slovenia
- Prior art keywords
- ketamine
- pharmaceuticals
- salt
- application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013190066 | 2013-09-13 | ||
| PCT/JP2014/004730 WO2015037248A1 (en) | 2013-09-13 | 2014-09-12 | Application of r-ketamine and salt thereof as pharmaceuticals |
| EP14793319.6A EP3043785B1 (en) | 2013-09-13 | 2014-09-12 | Application of r-ketamine and salt thereof as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3043785T1 true SI3043785T1 (sl) | 2022-02-28 |
Family
ID=51846870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201431903T SI3043785T1 (sl) | 2013-09-13 | 2014-09-12 | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9872841B2 (sl) |
| EP (2) | EP3964203A1 (sl) |
| JP (6) | JP6366439B2 (sl) |
| CA (2) | CA2923685C (sl) |
| CY (1) | CY1125290T1 (sl) |
| DK (1) | DK3043785T3 (sl) |
| ES (1) | ES2897453T3 (sl) |
| HR (1) | HRP20211629T1 (sl) |
| HU (1) | HUE056378T2 (sl) |
| LT (1) | LT3043785T (sl) |
| PL (1) | PL3043785T3 (sl) |
| PT (1) | PT3043785T (sl) |
| RS (1) | RS62516B1 (sl) |
| SI (1) | SI3043785T1 (sl) |
| WO (1) | WO2015037248A1 (sl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014152196A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| RS62516B1 (sr) | 2013-09-13 | 2021-11-30 | Univ Chiba Nat Univ Corp | Primena r-ketamina i njegove soli kao farmaceutskih proizvoda |
| CN107208133A (zh) | 2014-09-15 | 2017-09-26 | 詹森药业有限公司 | 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法 |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| JP6845162B2 (ja) | 2015-06-27 | 2021-03-17 | シェノックス・ファーマシューティカルズ・エルエルシー | ケタミン経皮送達システム |
| US11110070B2 (en) | 2015-11-17 | 2021-09-07 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| IL315066A (en) | 2016-10-27 | 2024-10-01 | Univ Chiba Nat Univ Corp | Pharmaceutical applications of (S)-norketamine and its salts |
| JP2021003001A (ja) * | 2017-09-07 | 2021-01-14 | 国立大学法人千葉大学 | うつ症状の検査方法、及び治療薬のスクリーニング方法 |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| JP7265990B2 (ja) * | 2017-09-27 | 2023-04-27 | 国立大学法人千葉大学 | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
| WO2019094596A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| SG11202005896WA (en) | 2017-12-22 | 2020-07-29 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| CN118453559A (zh) * | 2018-02-15 | 2024-08-09 | 国立大学法人千叶大学 | 炎症性疾病或骨病的预防或治疗剂及医药组合物 |
| US11426367B2 (en) * | 2018-05-04 | 2022-08-30 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| US11154537B2 (en) | 2018-08-10 | 2021-10-26 | Eleusis Therapeutics Us, Inc. | Method of treatment for ketamine infusion |
| WO2020138491A1 (ja) * | 2018-12-27 | 2020-07-02 | 国立大学法人千葉大学 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
| MX2021010683A (es) | 2019-03-05 | 2021-12-10 | Janssen Pharmaceuticals Inc | Esketamina para el tratamiento de la depresión. |
| CN112125816A (zh) * | 2020-03-17 | 2020-12-25 | 国药集团工业有限公司 | 一种氯胺酮、其衍生物或其盐的消旋化方法 |
| US20210299065A1 (en) * | 2020-03-27 | 2021-09-30 | Homeostasis Therapeutics, Limited | Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes |
| CN114306219B (zh) * | 2020-09-30 | 2023-09-26 | 四川普锐特药业有限公司 | 稳定的r-氯胺酮药物组合物 |
| WO2022118783A1 (ja) * | 2020-12-04 | 2022-06-09 | 国立大学法人大阪大学 | 治療抵抗性うつ病または緊急性を有するうつ病の症状を治療するための組成物 |
| CA3234818A1 (en) | 2021-10-12 | 2023-04-20 | Perception Neuroscience, Inc. | R-ketamine salts and methods of use thereof |
| WO2023178039A1 (en) | 2022-03-14 | 2023-09-21 | Perception Neuroscience, Inc. | Pharmaceutical formulations of r-ketamine |
| CN115006375A (zh) * | 2022-06-24 | 2022-09-06 | 华中科技大学 | 艾司氯胺酮用于制备治疗社交障碍药物的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3254124A (en) | 1962-06-29 | 1966-05-31 | Parke Davis & Co | Aminoketones and methods for their production |
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| US4670459A (en) | 1984-10-03 | 1987-06-02 | Merrell Dow Pharmaceuticals Inc. | Method of alleviating withdrawal symptoms |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| US5679714A (en) | 1995-06-07 | 1997-10-21 | Weg; Stuart L. | Administration of ketamine for detoxification and treatment of tobacco addiction |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| US7001609B1 (en) | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
| US6382204B1 (en) | 1999-10-14 | 2002-05-07 | Becton Dickinson And Company | Drug delivery system including holder and drug container |
| US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
| EP1257648B2 (en) | 2000-02-23 | 2016-09-14 | Amgen Inc. | Antagonistic selective binding agents of osteoprotegerin binding protein |
| BRPI0002693B8 (pt) | 2000-06-19 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| MXPA05000294A (es) | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| DE60327883D1 (de) | 2002-11-18 | 2009-07-16 | Yaupon Therapeutics Inc | Analgetische verwendung von (s)-norketamin |
| US7713440B2 (en) | 2003-10-08 | 2010-05-11 | Lyotropic Therapeutics, Inc. | Stabilized uncoated particles of reversed liquid crystalline phase materials |
| ME01956B (me) | 2005-09-28 | 2015-05-20 | Auris Medical Ag | Farmaceutske kompozicije za tretman poremećaja unutrašnjeg uva |
| US8785500B2 (en) | 2006-03-22 | 2014-07-22 | Icahn School Of Medicine At Mount Sinai | Intranasal administration of ketamine to treat depression |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| WO2014031975A1 (en) | 2012-08-23 | 2014-02-27 | Weg Stuart L | Anxiolytic composition, formulation and method of use |
| CN105073103A (zh) | 2013-03-15 | 2015-11-18 | 詹森药业有限公司 | S-盐酸氯胺酮的药物组合物 |
| WO2014152196A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| KR102424765B1 (ko) | 2013-04-12 | 2022-07-22 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 외상후 스트레스 장애의 치료 방법 |
| RS62516B1 (sr) | 2013-09-13 | 2021-11-30 | Univ Chiba Nat Univ Corp | Primena r-ketamina i njegove soli kao farmaceutskih proizvoda |
| CA2936809A1 (en) | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| US10098854B2 (en) | 2014-08-13 | 2018-10-16 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
| EP3085366A1 (en) | 2015-04-22 | 2016-10-26 | Institut du Cerveau et de la Moelle Epiniere-ICM | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior |
| US11426366B2 (en) | 2015-05-15 | 2022-08-30 | Arizona Board Of Regents On Behalf Of The Universsity Of Arizona | Compositions and methods for treating motor disorders |
| US11110070B2 (en) | 2015-11-17 | 2021-09-07 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| JP7265990B2 (ja) | 2017-09-27 | 2023-04-27 | 国立大学法人千葉大学 | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
| CN118453559A (zh) | 2018-02-15 | 2024-08-09 | 国立大学法人千叶大学 | 炎症性疾病或骨病的预防或治疗剂及医药组合物 |
| US11426367B2 (en) | 2018-05-04 | 2022-08-30 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2020138491A1 (ja) | 2018-12-27 | 2020-07-02 | 国立大学法人千葉大学 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
| US10973780B2 (en) | 2019-05-15 | 2021-04-13 | Bexson Biomedical, Inc. | Ketamine formulation for subcutaneous injection |
-
2014
- 2014-09-12 RS RS20211346A patent/RS62516B1/sr unknown
- 2014-09-12 ES ES14793319T patent/ES2897453T3/es active Active
- 2014-09-12 PL PL14793319T patent/PL3043785T3/pl unknown
- 2014-09-12 EP EP21192664.7A patent/EP3964203A1/en active Pending
- 2014-09-12 HU HUE14793319A patent/HUE056378T2/hu unknown
- 2014-09-12 EP EP14793319.6A patent/EP3043785B1/en active Active
- 2014-09-12 CA CA2923685A patent/CA2923685C/en active Active
- 2014-09-12 LT LTEPPCT/JP2014/004730T patent/LT3043785T/lt unknown
- 2014-09-12 CA CA3143962A patent/CA3143962A1/en active Pending
- 2014-09-12 DK DK14793319.6T patent/DK3043785T3/da active
- 2014-09-12 HR HRP20211629TT patent/HRP20211629T1/hr unknown
- 2014-09-12 US US15/021,003 patent/US9872841B2/en active Active
- 2014-09-12 WO PCT/JP2014/004730 patent/WO2015037248A1/en active Application Filing
- 2014-09-12 SI SI201431903T patent/SI3043785T1/sl unknown
- 2014-09-12 JP JP2014186056A patent/JP6366439B2/ja active Active
- 2014-09-12 PT PT147933196T patent/PT3043785T/pt unknown
-
2017
- 2017-12-21 US US15/849,698 patent/US10406121B2/en active Active
-
2018
- 2018-07-03 JP JP2018126684A patent/JP6615277B2/ja active Active
-
2019
- 2019-07-26 US US16/522,815 patent/US11207279B2/en active Active
- 2019-11-01 JP JP2019199496A patent/JP6842206B2/ja active Active
-
2021
- 2021-02-11 JP JP2021020280A patent/JP2021073310A/ja active Pending
- 2021-11-16 US US17/527,693 patent/US20220071929A1/en not_active Abandoned
- 2021-11-24 CY CY20211101022T patent/CY1125290T1/el unknown
-
2022
- 2022-11-27 JP JP2022188797A patent/JP7398836B2/ja active Active
-
2023
- 2023-11-28 JP JP2023200421A patent/JP2024009274A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220071929A1 (en) | 2022-03-10 |
| ES2897453T3 (es) | 2022-03-01 |
| JP2018145207A (ja) | 2018-09-20 |
| LT3043785T (lt) | 2021-12-10 |
| EP3043785B1 (en) | 2021-08-25 |
| RS62516B1 (sr) | 2021-11-30 |
| HRP20211629T1 (hr) | 2022-02-04 |
| CY1125290T1 (el) | 2023-03-24 |
| US9872841B2 (en) | 2018-01-23 |
| US20160220513A1 (en) | 2016-08-04 |
| PT3043785T (pt) | 2021-11-05 |
| JP2023011027A (ja) | 2023-01-20 |
| CA3143962A1 (en) | 2015-03-19 |
| JP2020015766A (ja) | 2020-01-30 |
| PL3043785T3 (pl) | 2022-02-28 |
| CA2923685A1 (en) | 2015-03-19 |
| EP3043785A1 (en) | 2016-07-20 |
| US20190343781A1 (en) | 2019-11-14 |
| DK3043785T3 (da) | 2021-11-15 |
| JP7398836B2 (ja) | 2023-12-15 |
| JP2021073310A (ja) | 2021-05-13 |
| CA2923685C (en) | 2022-03-08 |
| US20180177745A1 (en) | 2018-06-28 |
| JP6615277B2 (ja) | 2019-12-04 |
| HUE056378T2 (hu) | 2022-02-28 |
| JP2024009274A (ja) | 2024-01-19 |
| JP6366439B2 (ja) | 2018-08-01 |
| JP2015078181A (ja) | 2015-04-23 |
| US10406121B2 (en) | 2019-09-10 |
| WO2015037248A1 (en) | 2015-03-19 |
| US11207279B2 (en) | 2021-12-28 |
| EP3964203A1 (en) | 2022-03-09 |
| JP6842206B2 (ja) | 2021-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3043785T (lt) | R-ketamino ir jo druskų vartojimas kaip vaistų | |
| HK1254296A1 (zh) | 治療性化合物和其用途 | |
| IL243608A0 (en) | Substances with antiviral activity, preparations containing them and their uses | |
| HK1217092A1 (zh) | 治療性化合物及其用途 | |
| SG11201507897SA (en) | Salt of pyrazoloquinoline derivative, and crystal thereof | |
| HK1214255A1 (zh) | -醯基氨基噻唑衍生物或其鹽 | |
| PT2967044T (pt) | Composição herbicida e seu método de uso | |
| IL243613B (en) | Consequences of mutated pyrazolylpyrazole and its use as a herbicide | |
| IL243614A0 (en) | Consequences of mutated pyrazolylpyrazole and its use as a herbicide | |
| IL243615A0 (en) | Consequences of mutated pyrazolylpyrazole and its use as a herbicide | |
| HK1219691A1 (zh) | 醫藥組成物及其用途 | |
| GB201312698D0 (en) | Preparation and use of zinc compounds | |
| GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
| IL240177A (en) | Chromium-6-Iloxy-cycloalkanes are conserved and used as drugs | |
| HK1204916A1 (en) | Pharmaceutical application of anhydroicaritin | |
| IL240447A0 (en) | Propionic-biaryl acid derivatives and their use as pharmaceutical preparations | |
| IL243616A0 (en) | Consequences of mutated pyrazolylpyrazole and its use as a herbicide | |
| GB201303476D0 (en) | Agrochemical composition and method of use thereof | |
| IL240422B (en) | Bi-aryl derivatives of propionic acid and their use as medicinal preparations | |
| EP3052475A4 (en) | Pharmaceutical use of 3-benzylsulfonylpropionitrile | |
| AU2013902711A0 (en) | Compounds and methods of their use - IV | |
| GB201310349D0 (en) | Composition and method of use thereof | |
| GB201301928D0 (en) | Composition and method of use thereof |